AI Summary & Key Takeaways
AI InsightThe combined use of LTZ with rFSH resulted in a lower required dose of rFSH, a similar and ac ceptable endometrial thickness at the day of hCG administration, and comparable pregnancy rate compared with rFSH alone
📌 3 Key Takeaways
Özet
This study aimed to determine the outcomes of combined treatment of letrozole (LTZ) with recombinant follicle - stimulating hormone (rFSH) in comparison with rFSH alone in intrauterine insemination (IUI) cycles. This study consisted of 86 patients who experienced 106 IUI cycle s. Patients were classified into two treatment groups: group I underwent a combination of LTZ plus rFSH, and group II received rFSH alone. Ovulation was triggered with human chorionic gonadotropin (hCG), and IUI performed 36 hours later. The number of follicles ≥18 mm, endometrial thickness, required dose of FSH, duration of ovulation induction (OI), clinical pregnancy rates, multiple pregnancy rates, spontaneous abortion rates, and live birth rates were evaluated. The total required rFSH dose during the OI was significantly lower in the LTZ-rFSH combination group than the rFSH alone group (401.2±177.1 IU and 770.1±345.8 IU, respectively, p 0.05). The combined use of LTZ with rFSH resulted in a lower required dose of rFSH, a similar and ac ceptable endometrial thickness at the day of hCG administration, and comparable pregnancy rate compared with rFSH alone